Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.47
HSP's Cash to Debt is ranked lower than
66% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. HSP: 0.47 )
Ranked among companies with meaningful Cash to Debt only.
HSP' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.38 Max: N/A
Current: 0.47
Equity to Asset 0.53
HSP's Equity to Asset is ranked lower than
65% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. HSP: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
HSP' s Equity to Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.48 Max: 0.65
Current: 0.53
0.28
0.65
Interest Coverage 9.15
HSP's Interest Coverage is ranked lower than
77% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.03 vs. HSP: 9.15 )
Ranked among companies with meaningful Interest Coverage only.
HSP' s Interest Coverage Range Over the Past 10 Years
Min: 0.19  Med: 4.60 Max: 11.9
Current: 9.15
0.19
11.9
F-Score: 7
Z-Score: 4.76
M-Score: -2.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.36
HSP's Operating margin (%) is ranked higher than
65% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.51 vs. HSP: 13.36 )
Ranked among companies with meaningful Operating margin (%) only.
HSP' s Operating margin (%) Range Over the Past 10 Years
Min: 0.41  Med: 11.54 Max: 14.27
Current: 13.36
0.41
14.27
Net-margin (%) 8.95
HSP's Net-margin (%) is ranked higher than
61% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.44 vs. HSP: 8.95 )
Ranked among companies with meaningful Net-margin (%) only.
HSP' s Net-margin (%) Range Over the Past 10 Years
Min: -0.23  Med: 8.15 Max: 10.41
Current: 8.95
-0.23
10.41
ROE (%) 12.22
HSP's ROE (%) is ranked higher than
67% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. HSP: 12.22 )
Ranked among companies with meaningful ROE (%) only.
HSP' s ROE (%) Range Over the Past 10 Years
Min: -0.31  Med: 11.44 Max: 20.39
Current: 12.22
-0.31
20.39
ROA (%) 6.31
HSP's ROA (%) is ranked higher than
62% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. HSP: 6.31 )
Ranked among companies with meaningful ROA (%) only.
HSP' s ROA (%) Range Over the Past 10 Years
Min: -0.16  Med: 5.69 Max: 9.18
Current: 6.31
-0.16
9.18
ROC (Joel Greenblatt) (%) 22.10
HSP's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.81 vs. HSP: 22.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HSP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1.49  Med: 20.49 Max: 24.62
Current: 22.1
-1.49
24.62
Revenue Growth (3Y)(%) 2.20
HSP's Revenue Growth (3Y)(%) is ranked lower than
62% of the 581 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. HSP: 2.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HSP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.9  Med: 2.20 Max: 12.4
Current: 2.2
-0.9
12.4
EBITDA Growth (3Y)(%) 29.60
HSP's EBITDA Growth (3Y)(%) is ranked higher than
86% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. HSP: 29.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HSP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.7  Med: -0.50 Max: 29.6
Current: 29.6
-32.7
29.6
» HSP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

HSP Guru Trades in Q4 2014

Jim Simons 631,695 sh (+95.51%)
Mario Gabelli 352,370 sh (+38.25%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Joel Greenblatt Sold Out
Jeff Auxier 126,907 sh (-0.31%)
Vanguard Health Care Fund 7,966,970 sh (-4.87%)
John Rogers 2,311,309 sh (-5.02%)
Paul Tudor Jones 19,798 sh (-20.47%)
» More
Q1 2015

HSP Guru Trades in Q1 2015

Jeremy Grantham 657,484 sh (New)
Mario Gabelli 834,303 sh (+136.77%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
John Rogers Sold Out
Vanguard Health Care Fund Sold Out
Jeff Auxier 119,147 sh (-6.11%)
Jeff Auxier 57,665 sh (-54.56%)
Paul Tudor Jones 5,652 sh (-71.45%)
Jim Simons 93,800 sh (-85.15%)
» More
Q2 2015

HSP Guru Trades in Q2 2015

George Soros 172,139 sh (New)
Paul Tudor Jones 318,431 sh (+5533.95%)
Jim Simons 307,400 sh (+227.72%)
Jeremy Grantham 1,144,500 sh (+74.07%)
Mario Gabelli 1,018,420 sh (+22.07%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Jeff Auxier 118,472 sh (-0.57%)
» More
Q3 2015

HSP Guru Trades in Q3 2015

Jim Simons Sold Out
George Soros Sold Out
Robert Bruce Sold Out
Michael Price Sold Out
Jeremy Grantham Sold Out
Jeff Auxier Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with HSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Hospira Inc

Mario Gabelli Comments on Hospira Inc. - Oct 19, 2015

Hospira Inc. (NYSE:HSP), based in Lake Forest, Illinois, is the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars. On February 5, 2015, the company received a $90 per share cash merger offer from Pfizer Inc., valuing Hospira at $15.2 billion. The transaction closed on September 3, 2015, following shareholder and regulatory approvals, and the deal created a leading global injectables business. The Fund earned an annualized return of 5.82%.



From Mario Gabelli (Trades, Portfolio)'s ABC Fund third quarter commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Hospira Inc

Michael Price Sells Holding in Hospira Guru adds to stakes in Dolby Laboratories and United States Steel
Michael Price (Trades, Portfolio) is known to prefer out-of-favor small cap companies that offer good value when he makes his investment decisions, and many of his third-quarter transactions fit that description, but some of his largest transactions involved companies with caps that exceeded several billion dollars. Read more...
Sells and Additions in Third Quarter Have Greatest Impact on Mario Gabelli's Portfolio Guru adds nearly four dozen new stakes
Mario Gabelli (Trades, Portfolio) of GAMCO Investors bought nearly four dozen stakes in the third quarter that are new to his portfolio, but his sales of existing stakes and additions to others had more of an impact on it. Read more...
Mario Gabelli Comments on Hospira Inc. Guru stock highlight
Hospira Inc. (NYSE:HSP), based in Lake Forest, Illinois, is the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars. On February 5, 2015, the company received a $90 per share cash merger offer from Pfizer Inc., valuing Hospira at $15.2 billion. The transaction closed on September 3, 2015, following shareholder and regulatory approvals, and the deal created a leading global injectables business. The Fund earned an annualized return of 5.82%. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 37.80
HSP's P/E(ttm) is ranked lower than
68% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.86 vs. HSP: 37.80 )
Ranked among companies with meaningful P/E(ttm) only.
HSP' s P/E(ttm) Range Over the Past 10 Years
Min: 8.48  Med: 25.93 Max: 133.97
Current: 37.8
8.48
133.97
Forward P/E 27.93
HSP's Forward P/E is ranked lower than
75% of the 419 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.50 vs. HSP: 27.93 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 37.80
HSP's PE(NRI) is ranked lower than
63% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.45 vs. HSP: 37.80 )
Ranked among companies with meaningful PE(NRI) only.
HSP' s PE(NRI) Range Over the Past 10 Years
Min: 8.48  Med: 25.88 Max: 135
Current: 37.8
8.48
135
P/B 4.30
HSP's P/B is ranked lower than
78% of the 928 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.54 vs. HSP: 4.30 )
Ranked among companies with meaningful P/B only.
HSP' s P/B Range Over the Past 10 Years
Min: 1.52  Med: 2.98 Max: 5.72
Current: 4.3
1.52
5.72
P/S 3.37
HSP's P/S is ranked lower than
65% of the 929 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.60 vs. HSP: 3.37 )
Ranked among companies with meaningful P/S only.
HSP' s P/S Range Over the Past 10 Years
Min: 0.99  Med: 2.01 Max: 3.37
Current: 3.37
0.99
3.37
PFCF 80.31
HSP's PFCF is ranked lower than
81% of the 485 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.85 vs. HSP: 80.31 )
Ranked among companies with meaningful PFCF only.
HSP' s PFCF Range Over the Past 10 Years
Min: 8.32  Med: 28.67 Max: 203.78
Current: 80.31
8.32
203.78
POCF 23.18
HSP's POCF is ranked lower than
51% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.68 vs. HSP: 23.18 )
Ranked among companies with meaningful POCF only.
HSP' s POCF Range Over the Past 10 Years
Min: 5.95  Med: 13.31 Max: 50.76
Current: 23.18
5.95
50.76
EV-to-EBIT 26.53
HSP's EV-to-EBIT is ranked lower than
66% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.42 vs. HSP: 26.53 )
Ranked among companies with meaningful EV-to-EBIT only.
HSP' s EV-to-EBIT Range Over the Past 10 Years
Min: -227.4  Med: 18.80 Max: 152.9
Current: 26.53
-227.4
152.9
EV-to-EBITDA 19.01
HSP's EV-to-EBITDA is ranked lower than
61% of the 852 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. HSP: 19.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
HSP' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 19.01
Current: 19.01
0
19.01
Shiller P/E 64.18
HSP's Shiller P/E is ranked lower than
66% of the 166 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.90 vs. HSP: 64.18 )
Ranked among companies with meaningful Shiller P/E only.
HSP' s Shiller P/E Range Over the Past 10 Years
Min: 18.44  Med: 31.64 Max: 65.01
Current: 64.18
18.44
65.01
Current Ratio 2.52
HSP's Current Ratio is ranked higher than
55% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. HSP: 2.52 )
Ranked among companies with meaningful Current Ratio only.
HSP' s Current Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.51 Max: 3.03
Current: 2.52
1.61
3.03
Quick Ratio 1.50
HSP's Quick Ratio is ranked lower than
54% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. HSP: 1.50 )
Ranked among companies with meaningful Quick Ratio only.
HSP' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 1.48 Max: 2.04
Current: 1.5
1
2.04
Days Inventory 155.02
HSP's Days Inventory is ranked lower than
68% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.42 vs. HSP: 155.02 )
Ranked among companies with meaningful Days Inventory only.
HSP' s Days Inventory Range Over the Past 10 Years
Min: 105.6  Med: 125.19 Max: 139.51
Current: 155.02
105.6
139.51
Days Sales Outstanding 46.30
HSP's Days Sales Outstanding is ranked higher than
75% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.67 vs. HSP: 46.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
HSP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.46  Med: 54.37 Max: 59.38
Current: 46.3
45.46
59.38
Days Payable 49.70
HSP's Days Payable is ranked lower than
69% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. HSP: 49.70 )
Ranked among companies with meaningful Days Payable only.
HSP' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 49.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.42
HSP's Price/Tangible Book is ranked lower than
70% of the 889 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. HSP: 6.42 )
Ranked among companies with meaningful Price/Tangible Book only.
HSP' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.04  Med: 5.64 Max: 76.38
Current: 6.42
3.04
76.38
Price/Projected FCF 3.37
HSP's Price/Projected FCF is ranked lower than
63% of the 523 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. HSP: 3.37 )
Ranked among companies with meaningful Price/Projected FCF only.
HSP' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.91  Med: 1.37 Max: 3.45
Current: 3.37
0.91
3.45
Price/Median PS Value 1.68
HSP's Price/Median PS Value is ranked lower than
73% of the 899 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. HSP: 1.68 )
Ranked among companies with meaningful Price/Median PS Value only.
HSP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.59  Med: 0.99 Max: 1.66
Current: 1.68
0.59
1.66
Price/Graham Number 3.27
HSP's Price/Graham Number is ranked lower than
68% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.21 vs. HSP: 3.27 )
Ranked among companies with meaningful Price/Graham Number only.
HSP' s Price/Graham Number Range Over the Past 10 Years
Min: 1.86  Med: 2.71 Max: 9.97
Current: 3.27
1.86
9.97
Earnings Yield (Greenblatt) (%) 3.80
HSP's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 720 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. HSP: 3.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HSP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.7  Med: 4.90 Max: 10.1
Current: 3.8
0.7
10.1
Forward Rate of Return (Yacktman) (%) -4.88
HSP's Forward Rate of Return (Yacktman) (%) is ranked lower than
71% of the 318 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.62 vs. HSP: -4.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HSP' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -1.6  Med: 9.40 Max: 18.4
Current: -4.88
-1.6
18.4

More Statistics

Revenue(Mil) $4636
EPS $ 2.38
Short Percentage of Float1.03%
52-Week Range $46.56 - 90.63
Shares Outstanding(Mil)172.93

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 4,638 5,018
EPS($) 2.54 3.22
EPS without NRI($) 2.54 3.22

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:HOS.Germany,
Hospira Inc was incorporated in Delaware on September 16, 2003. The Company is a provider of injectable drugs and infusion technologies, and is also engaged in developing, manufacturing, marketing and distribution. Its portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company's business segments are Specialty Injectable Pharmaceuticals, Medication Management and Other Pharmaceuticals. Specialty Injectable Pharmaceuticals consists of generic injectable pharmaceuticals products. Generic injectable pharmaceuticals provide customers with a lower-cost alternative to branded products when associated patent protection expires, when patents are declared invalid, or when the generic products do not infringe the patents of others. Our generic injectable pharmaceuticals are sold in therapeutic areas including analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other. Medication Management offer the Hospira MedNet safety software system, which is designed for hospitals to customize intravenous drug dosage limits and track drug delivery to prevent medication errors. The wireless network version of the Hospira MedNet system establishes real-time send-and-receive capability and can interface with select hospital and pharmacy information systems. Other Pharmaceuticals primarily consists of large volume I.V. solutions, nutritionals and contract manufacturing services. We offer infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for washing and cleansing of wounds or surgical sites. The Company's primary customers include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its competitors include Baxter International Inc.; Becton, Dickinson and Company; Fresenius Kabi AG; Mallinckrodt plc; Mylan Inc; Par Pharmaceuticals Companies, Inc.; Pfizer Inc.; Sandoz; Sanofi S.A. and Teva Pharmaceuticals, Aspen Medical; Fresenius Kabi; Pfizer; Sandoz and a number of smaller competitors and the originator companies. The Company's operations and business activities are subject to extensive legal and regulatory requirements that are enforced by numerous governmental agencies in the countries in which it do business.
» More Articles for HSP

Headlines

Articles On GuruFocus.com
Michael Price Sells Holding in Hospira Dec 04 2015 
Auxier Buys New Stake in Allstate Nov 13 2015 
Sells and Additions in Third Quarter Have Greatest Impact on Mario Gabelli's Portfolio Oct 25 2015 
Mario Gabelli Comments on Hospira Inc. Oct 19 2015 
The Gabelli ABC Merger and Arbitrage Fund Q3 Shareholder Commentary Oct 19 2015 
Pfizer Nears Completion of Hospira Acquisition Aug 26 2015 
Weekly 52-Week Highs Highlight: Tim Hortons, Hospira, Kinder Morgan, Sigma-Aldrich Aug 25 2015 
Skyworks Solutions Tops Highest-Performing S&P 500 Stocks Jun 05 2015 
John Rogers' Ariel Fund Q1 2015 Commentary Apr 16 2015 
Weekly 52-Week Highs Highlight: SIAL, GIS, TJX, HSP Mar 30 2015 

More From Other Websites
Pfizer earnings fall on strong dollar, higher expenses Feb 02 2016
Novartis profits jump 73% on asset sales Jan 27 2016
What Pfizer-Allergan means for manufacturing plant in Rocky Mount Nov 23 2015
Pfizer, Allergan weigh blockbuster merger: reports Oct 29 2015
Pfizer Updates 2015 Financial Guidance Solely to Include Hospira Operations In Financial Results... Sep 30 2015
India-based company doesn't want drug used for executions Sep 22 2015
India-based company doesn't want drug used for executions Sep 22 2015
APNewsBreak: Arkansas execution plan may use UK firm's drug Sep 18 2015
APNewsBreak: Arkansas execution plan may use UK firm's drug Sep 18 2015
Pfizer Inc. -- Moody's assigns A1 to Pfizer's proposed exchange notes Sep 03 2015
Pfizer Inc. Commences Exchange Offers for Hospira Notes Sep 03 2015
Ex-Hospira CEO Trades Shares for $91 Million Cash in Pfizer Deal Sep 03 2015
HOSPIRA INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of... Sep 03 2015
Pfizer Completes Acquisition of Hospira Sep 03 2015
Pfizer Completes Acquisition of Hospira Sep 03 2015
Two steady stocks among S&P 500 Sep 02 2015
S&P 500 picks up ATVI and UAL Aug 28 2015
Ahead of the Bell: Activision Blizzard, United join S&P 500 Aug 28 2015
Ahead of the Bell: Activision Blizzard, United join S&P 500 Aug 28 2015
Activision Blizzard, United Continental Holdings Set to Join the S&P 500 Aug 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK